|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-8-30
|
|
pubmed:abstractText |
Ultimately, patients with metastatic prostate cancer progress on androgen ablation therapy. The investigation of new chemotherapeutic regimens for the treatment of androgen-independent prostate cancer (AIPC) is essential. The authors conducted a Phase II trial with vinorelbine, doxorubicin, and daily prednisone (NAP) to investigate the antitumor activity and palliative response of this regimen in patients with AIPC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
107
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1093-100
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16888761-Aged,
pubmed-meshheading:16888761-Aged, 80 and over,
pubmed-meshheading:16888761-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16888761-Doxorubicin,
pubmed-meshheading:16888761-Drug Administration Schedule,
pubmed-meshheading:16888761-Humans,
pubmed-meshheading:16888761-Male,
pubmed-meshheading:16888761-Middle Aged,
pubmed-meshheading:16888761-Neoplasm Metastasis,
pubmed-meshheading:16888761-Pain Measurement,
pubmed-meshheading:16888761-Palliative Care,
pubmed-meshheading:16888761-Prednisone,
pubmed-meshheading:16888761-Prostate-Specific Antigen,
pubmed-meshheading:16888761-Prostatic Neoplasms,
pubmed-meshheading:16888761-Vinblastine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
|
|
pubmed:affiliation |
Department of Urology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
